These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18829514)

  • 1. A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.
    Hensley ML; Larkin J; Fury M; Gerst S; Tai DF; Sabbatini P; Konner J; Orlando M; Goss TL; Aghajanian CA
    Clin Cancer Res; 2008 Oct; 14(19):6310-6. PubMed ID: 18829514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
    Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors.
    Kalykaki A; Vamvakas L; Agelaki S; Kalbakis K; Vardakis N; Sfakiotaki G; Ignatiadis M; Saridaki Z; Karampeazis A; Mavroudis D; Georgoulias V
    Oncology; 2006; 71(3-4):197-203. PubMed ID: 17641541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.
    Hutson TE; Vukelja S; Atienza D; Awasthi S; Delaune R; Deutsch M; Dien PY; Gregory TF; Kolodziej MJ; Muscato JJ; Raju RN; Ruxer RL; Mull S; Ilegbodu D; Hood K; Nicol S; Berry W
    Invest New Drugs; 2008 Apr; 26(2):151-8. PubMed ID: 18236006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.
    Richards DA; Loesch D; Vukelja SJ; Wu H; Hyman WJ; Nieves J; Wang Y; Hu S; Shonukan OO; Tai DF
    Invest New Drugs; 2011 Oct; 29(5):963-70. PubMed ID: 20352294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.
    Fury MG; Haque S; Stambuk H; Shen R; Carlson D; Pfister D
    Cancer; 2011 Feb; 117(4):795-801. PubMed ID: 20922785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.
    Misset JL; Gamelin E; Campone M; Delaloge S; Latz JE; Bozec L; Fumoleau P
    Ann Oncol; 2004 Jul; 15(7):1123-9. PubMed ID: 15205208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.
    Takimoto CH; Hammond-Thelin LA; Latz JE; Forero L; Beeram M; Forouzesh B; de Bono J; Tolcher AW; Patnaik A; Monroe P; Wood L; Schneck KB; Clark R; Rowinsky EK
    Clin Cancer Res; 2007 May; 13(9):2675-83. PubMed ID: 17473199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.
    Pippen J; Elias AD; Neubauer M; Stokoe C; Vaughn LG; Wang Y; Orlando M; Shonukan O; Muscato J; O'Shaughnessy JA; Gralow J
    Clin Breast Cancer; 2010 Apr; 10(2):148-53. PubMed ID: 20299319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943.
    Alberts SR; Sande JR; Foster NR; Quevedo FJ; McWilliams RR; Kugler JW; Fitch TR; Jaslowski AJ
    J Gastrointest Cancer; 2007; 38(2-4):87-94. PubMed ID: 19023677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
    Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
    Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of vinflunine and pemetrexed in refractory solid tumors.
    Sanoff HK; Davies J; Walko C; Buie L; Chiu WK; Ivanova A; O'Neil B; Stinchcombe TE; Keller K; Dees EC
    Invest New Drugs; 2011 Feb; 29(1):131-6. PubMed ID: 19830387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
    Simon GR; Verschraegen CF; Jänne PA; Langer CJ; Dowlati A; Gadgeel SM; Kelly K; Kalemkerian GP; Traynor AM; Peng G; Gill J; Obasaju CK; Kindler HL
    J Clin Oncol; 2008 Jul; 26(21):3567-72. PubMed ID: 18640937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.
    Treat J; Bonomi P; McCleod M; Christiansen NP; Mintzer DM; Monberg MJ; Ye Z; Chen R; Obasaju CK
    Lung Cancer; 2006 Jul; 53(1):77-83. PubMed ID: 16730854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer.
    Spigel DR; Hainsworth JD; Barton JH; Patton JF; Zubkus JD; Simons L; Griner P; Burris HA; Greco FA
    J Thorac Oncol; 2010 Jun; 5(6):841-5. PubMed ID: 20421819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
    Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
    Dy GK; Suri A; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Atherton PJ; Hanson LJ; Burch PA; Rubin J; Erlichman C; Adjei AA
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):522-30. PubMed ID: 15754203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
    Attia S; Morgan-Meadows S; Holen KD; Bailey HH; Eickhoff JC; Schelman WR; Traynor AM; Mulkerin DL; Campbell TC; McFarland TA; Huie MS; Cleary JF; Tevaarwerk AJ; Alberti DB; Wilding G; Liu G
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):45-51. PubMed ID: 18841362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
    Chow LQ; Blais N; Jonker DJ; Laurie SA; Diab SG; Canil C; McWilliam M; Thall A; Ruiz-Garcia A; Zhang K; Tye L; Chao RC; Camidge DR
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):709-22. PubMed ID: 21989766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.